

# Harald HÃ¼bner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6172473/publications.pdf>

Version: 2024-02-01

51  
papers

1,961  
citations

430874

18  
h-index

265206

42  
g-index

52  
all docs

52  
docs citations

52  
times ranked

2743  
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure-based discovery of opioid analgesics with reduced side effects. <i>Nature</i> , 2016, 537, 185-190.	27.8	744
2	Conjugated Enynes as Nonaromatic Catechol Bioisosteres: Synthesis, Binding Experiments, and Computational Studies of Novel Dopamine Receptor Agonists Recognizing Preferentially the D3 Subtype. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 756-762.	6.4	170
3	Covalent agonists for studying G protein-coupled receptor activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10744-10748.	7.1	82
4	Structure-guided development of heterodimer-selective GPCR ligands. <i>Nature Communications</i> , 2016, 7, 12298.	12.8	81
5	Binding pathway determines norepinephrine selectivity for the human $\beta$ <sup>2</sup> 1AR over $\beta$ <sup>2</sup> 2AR. <i>Cell Research</i> , 2021, 31, 569-579.	12.0	65
6	Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12046-12050.	7.1	64
7	Conformational Complexity and Dynamics in a Muscarinic Receptor Revealed by NMR Spectroscopy. <i>Molecular Cell</i> , 2019, 75, 53-65.e7.	9.7	59
8	Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5- <i>a</i> ]pyridine Substructure. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2908-2929.	6.4	55
9	An allosteric modulator binds to a conformational hub in the $\beta$ <sup>2</sup> adrenergic receptor. <i>Nature Chemical Biology</i> , 2020, 16, 749-755.	8.0	51
10	Molecular Determinants of Biased Agonism at the Dopamine D <sub>2</sub> Receptor. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2703-2717.	6.4	42
11	Dual-Acting Cholinesterase- and Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9078-9102.	6.4	35
12	Mimicking of Arginine by Functionalized N-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1925-1945.	6.4	34
13	Structure-based development of a subtype-selective orexin 1 receptor antagonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18059-18067.	7.1	33
14	Visualization of $\beta$ <sup>2</sup> -adrenergic receptor dynamics and differential localization in cardiomyocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	30
15	Fast and Efficient <sup>18</sup> F-Labeling by [ <sup>18</sup> F]Fluorophenylazocarboxylic Esters. <i>Chemistry - A European Journal</i> , 2014, 20, 370-375.	3.3	29
16	Identification of the Beer Component Hordenine as Food-Derived Dopamine D2 Receptor Agonist by Virtual Screening a 3D Compound Database. <i>Scientific Reports</i> , 2017, 7, 44201.	3.3	27
17	Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M <sub>2</sub> Muscarinic Acetylcholine Receptor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3314-3334.	6.4	25
18	Selective and Wash-Resistant Fluorescent Dihydrocodeinone Derivatives Allow Single-Molecule Imaging of $\mu$ -Opioid Receptor Dimerization. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 5958-5964.	13.8	23

#	ARTICLE	IF	CITATIONS
19	$\hat{I}^2$ -Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5613-5628.	3.0	20
20	Heterodimerization of Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Leads to Increased M <sub>2</sub> R Affinity and Selectivity. <i>ACS Omega</i> , 2017, 2, 6741-6754.	3.5	19
21	In Vivo Monitoring of the Antiangiogenic Effect of Neurotensin Receptor-Mediated Radiotherapy by Small-Animal Positron Emission Tomography: A Pilot Study. <i>Pharmaceuticals</i> , 2014, 7, 464-481.	3.8	18
22	Monitoring of the dopamine D2 receptor agonists hordenine and N-methyltyramine during the brewing process and in commercial beer samples. <i>Food Chemistry</i> , 2019, 276, 745-753.	8.2	18
23	Development of Covalent Ligand-Receptor Pairs to Study the Binding Properties of Nonpeptidic Neurotensin Receptor 1 Antagonists. <i>ACS Chemical Biology</i> , 2016, 11, 869-875.	3.4	17
24	Fluorescence Labeling of Neurotensin(8-13) via Arginine Residues Gives Molecular Tools with High Receptor Affinity. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 16-22.	2.8	17
25	Structure-based development of caged dopamine D2/D3 receptor antagonists. <i>Scientific Reports</i> , 2020, 10, 829.	3.3	14
26	Fluorescent ligands for dopamine D2/D3 receptors. <i>Scientific Reports</i> , 2020, 10, 21842.	3.3	14
27	Visualization of ligand-induced dopamine D2S and D2L receptor internalization by TIRF microscopy. <i>Scientific Reports</i> , 2017, 7, 10894.	3.3	13
28	[ <sup>18</sup> F]Fluorophenylazocarboxylates: Design and Synthesis of Potential Radioligands for Dopamine D3 and $\hat{I}^4$ -Opioid Receptor. <i>ACS Omega</i> , 2017, 2, 8649-8659.	3.5	13
29	Conjugation of Short Peptides to Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Determines M <sub>2</sub> R Selectivity. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5358-5369.	6.4	13
30	Red-Emitting Dibenzodiazepinone Derivatives as Fluorescent Dualsteric Probes for the Muscarinic Acetylcholine M2 Receptor. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4133-4154.	6.4	13
31	Hybridization of $\hat{I}^2$ -Adrenergic Agonists and Antagonists Confers G Protein Bias. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5111-5131.	6.4	12
32	Structural insights into ligand recognition, activation, and signaling of the $\hat{I}^2$ adrenergic receptor. <i>Science Advances</i> , 2022, 8, eabj5347.	10.3	12
33	Dibenzo[ b , f ][1,4]oxazepines and dibenzo[ b , e ]oxepines: Influence of the chlorine substitution pattern on the pharmacology at the H <sub>1</sub> R, H <sub>4</sub> R, 5-HT <sub>2A</sub> R and other selected GPCRs. <i>Pharmacological Research</i> , 2016, 113, 610-625.	7.1	11
34	Synthesis and evaluation of fluoro substituted pyridinylcarboxamides and their phenylazo analogues for potential dopamine D3 receptor PET imaging. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5399-5403.	2.2	10
35	Potent haloperidol derivatives covalently binding to the dopamine D2 receptor. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5084-5094.	3.0	10
36	Perquinolines A-C: Unprecedented Bacterial Tetrahydroisoquinolines Involving an Intriguing Biosynthesis. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 12930-12934.	13.8	10

#	ARTICLE	IF	CITATIONS
37	Homobivalent Dopamine D2 Receptor Ligands Modulate the Dynamic Equilibrium of D2 Monomers and Homo- and Heterodimers. ACS Chemical Biology, 2021, 16, 371-379.	3.4	10
38	Benzyl Phenylsemicarbazides: A Chemistry-Driven Approach Leading to G Protein-Biased Dopamine D <sub>4</sub> Receptor Agonists with High Subtype Selectivity. Journal of Medicinal Chemistry, 2019, 62, 9658-9679.	6.4	9
39	Abolishing Dopamine D <sub>2</sub> /D <sub>3</sub> Receptor Affinity of Subtype-Selective Carbamoylguanidine-Type Histamine H <sub>2</sub> Receptor Agonists. Journal of Medicinal Chemistry, 2021, 64, 8684-8709.	6.4	8
40	Selective and Wash-Resistant Fluorescent Dihydrocodeinone Derivatives Allow Single-Molecule Imaging of $\mu$ -Opioid Receptor Dimerization. Angewandte Chemie, 2020, 132, 6014-6020.	2.0	5
41	Regiospecific Introduction of Halogens on the 2-Aminobiphenyl Subunit Leading to Highly Potent and Selective M3 Muscarinic Acetylcholine Receptor Antagonists and Weak Inverse Agonists. Journal of Medicinal Chemistry, 2020, 63, 4349-4369.	6.4	5
42	Fluoro-substituted phenylazocarboxamides: Dopaminergic behavior and N-arylation properties for irreversible binding. Bioorganic and Medicinal Chemistry, 2015, 23, 3938-3947.	3.0	4
43	Structure-based exploration of an allosteric binding pocket in the NTS1 receptor using bitopic NT(8-13) derivatives and molecular dynamics simulations. Journal of Molecular Modeling, 2019, 25, 193.	1.8	4
44	Synthesis, Radiosynthesis and Biological Evaluation of Buprenorphine-Derived Phenylazocarboxamides as Novel $\mu$ -Opioid Receptor Ligands. ChemMedChem, 2020, 15, 1175-1186.	3.2	4
45	Presynaptic vesicular accumulation is required for antipsychotic efficacy in psychotic-like rats. Journal of Psychopharmacology, 2021, 35, 65-77.	4.0	4
46	Functionally selective activation of the dopamine receptor D2 is mirrored by the protein expression profiles. Scientific Reports, 2021, 11, 3501.	3.3	2
47	Innenrücktitelbild: Selective and Wash-Resistant Fluorescent Dihydrocodeinone Derivatives Allow Single-Molecule Imaging of $\mu$ -Opioid Receptor Dimerization (Angew. Chem. 15/2020). Angewandte Chemie, 2020, 132, 6348-6348.	2.0	1
48	Optimizing the Expression of Human Dopamine Receptors in Escherichia coli. International Journal of Molecular Sciences, 2021, 22, 8647.	4.1	1
49	Development of disulfide-functionalized peptides covalently binding G protein-coupled receptors. Bioorganic and Medicinal Chemistry, 2022, 61, 116720.	3.0	1
50	Perquinoline...: neuartige bakterielle Tetrahydroisochinoline mit einer bemerkenswerten Biosynthese. Angewandte Chemie, 2019, 131, 13063-13068.	2.0	0
51	Strukturbasierte Entwicklung von G-Protein bevorzugenden $\mu$ -Opioidrezeptor Agonisten. Angewandte Chemie, 2022, 134, .	2.0	0